The first pill shown to treat COVID-19 has moved one step closer to being available to the public. The pharmaceutical company Merck requested FDA emergency authorization Monday for their COVID-19 ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

Add Yahoo as a preferred source to see more of our stories on Google. By now, most people have reached a resigned acceptance when it comes to COVID-19. We accept that we’re probably going to get ...

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...

Pfizer said Tuesday morning that final trial studies still show its experimental COVID-19 pill significantly reduced the risk of hospitalization or death linked to the virus, by 89%. The company also ...

Pfizer announced on Wednesday that it has started clinical trials that could lead to the antiviral pill Paxlovid being available for children ages six and up to reduce the severity and duration of ...

A pill has cut the risk of hospitalization or death from Covid-19 by half in a study, Merck and Ridgeback Biotherapeutics said Friday. It would become the first oral medicine that fights viral ...

But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific conference in San ...